AllTrna
1 known investors
Alltrna develops engineered, chemically modified tRNA oligonucleotides as programmable medicines, using proprietary machine learning tools to design tRNA molecules with desired pharmacologic properties. Its initial therapeutic focus is treating nonsense mutations by reading through premature termination codons to restore full-length protein production, addressing a category it calls Stop Codon Disease.
AI & Machine LearningBiotechDeep TechHealthtech
Founders & leadership
MW
Michelle WernerCEO
LA
Lovisa AfzeliusExecutive Chair & Founding CEO
JP
Joanne ProtanoPresident & Chief Financial Officer
DH
Dave HavaChief Scientific Officer
NK
Nerissa KreherChief Medical Officer
CK
Caroline KöhrerSVP, Discovery Platform
Investors · 1
Frequently asked questions
- What does AllTrna do?
- Alltrna develops engineered, chemically modified tRNA oligonucleotides as programmable medicines, using proprietary machine learning tools to design tRNA molecules with desired pharmacologic properties. Its initial therapeutic focus is treating nonsense mutations by reading through premature termination codons to restore full-length protein production, addressing a category it calls Stop Codon Disease.
- Who are AllTrna's investors?
- AllTrna's investors include Flagship Pioneering.